Loading patent…
AssigneeSt. Jude Medical, Inc.
InventorsPaul Edward Ashworth, Matthew Frank Ogle, Daniel Paul McTavish, Sheila Jeanne Kelly, Andrea L. Johnson
Estimating the term…
Crosslinked tissue is contacted with one or more toxicity reducing solutions to remove cytotoxicity associated with the crosslinking process. In particular, crosslinked tissue can be contacted with an inorganic sulfur-oxygen group to form chemical adducts of aldehydes and the inorganic sulfur-oxygen group. Preferably, the cytotoxicity reduced crosslinked tissue has no residual cytotoxicity. In preferred embodiments, a plurality of toxicity reducing agents are used to detoxify the tissue. Preferred toxicity reducing agents include, for example, inorganic sulfur-oxygen ions, such as bisulfate and thiosulfate, organic sulfates, amines, ammonia/ammonium, and surfactants.
A prosthetic tissue comprising a chemically crosslinked protein matrix comprising aldehyde adducts, the protein matrix having immunological rejection sufficiently suppressed to permit xenograft transplantation and the protein matrix having no detectable cytotoxicity as evaluated in a culture medium without any added growth factors.
A prosthetic tissue comprising a protein matrix crosslinked with a multifunctional aldehyde and soaked in formaldehyde having extractable residual aldehyde compound concentrations of no more than about 5×10−4 moles of aldehyde per gram of dry tissue.
A prosthetic tissue comprising adducts of aldehyde groups and inorganic sulfur-oxygen groups.
A prosthetic tissue comprising adducts of aldehyde groups and ammonia/ammonium groups and adducts of aldehyde groups and sulfur-oxygen groups.
Dependencies are inferred from the claim text.